AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Mitochondrial enolase superfamily member 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q7L5Y1

UPID:

ENOF1_HUMAN

Alternative names:

Antisense RNA to thymidylate synthase; L-fuconate dehydratase

Alternative UPACC:

Q7L5Y1; A6NMP3; A8K9R5; B3KSL6; B3KXE4; D3DUH0; Q15407; Q15594; Q15595; Q6ZS08; Q9HAS5; Q9HAS6

Background:

Mitochondrial enolase superfamily member 1, also known as Antisense RNA to thymidylate synthase and L-fuconate dehydratase, plays a crucial role in the catabolism of L-fucose. This process involves the dehydration of L-fuconate to 2-keto-3-deoxy-L-fuconate, a reaction essential for the metabolism of carbohydrates attached to cellular glycoproteins.

Therapeutic significance:

The protein's involvement in Dyskeratosis congenita, digenic, highlights its potential as a target for therapeutic intervention. Understanding the role of Mitochondrial enolase superfamily member 1 could open doors to potential therapeutic strategies, especially considering its impact on telomere maintenance and the pathogenic mechanism involving ENOSF1-TYMS RNA-RNA interactions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.